Trial Profile
A Double-blind Randomized Study to Determine the Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2022
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Insulin
- Indications Prediabetic state
- Focus Therapeutic Use
- 07 Jun 2022 Results evaluating effects of empagliflozin on pancreatic fat content and insulin secretion in persons with prediabetes, presented at the 82nd Annual Scientific Sessions of the American Diabetes Association
- 29 Oct 2021 Primary endpoint (effect of treatment with 25 mg empagliflozin daily versus placebo on regional brain insulin sensitivity) has been met as per results published in the Diabetes Care
- 29 Oct 2021 Results published in the Diabetes Care